💊the U.S. Food and Drug Administration has approved

💊the U.S. Food and Drug Administration has approved

Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® . . .

https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_fda_approval_for_sutent_sunitinib_malate_as_first_and_only_adjuvant_treatment_for_adult_patients_at_high_risk_of_recurrent_renal_cell_carcinoma

FDA approves Roche’s Hemlibra (emicizumab-kxwh) for haemophilia A with inhibitors – Roche Media News

Roche today announced that the US Food and Drug Administration (FDA) has approved Hemlibra® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with haemophilia A with factor VIII inhibitors.

https://www.roche.com/media/store/releases/med-cor-2017-11-16.htm

FDA approves new treatment to prevent bleeding in certain patients with hemophilia A

FDA approves new treatment to prevent or reduce frequency of bleeding episodes in patients with hemophilia A who have Factor VIII inhibitors.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585567.htm

FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma

Roche announced today that the US Food and Drug Administration (FDA) approved Gazyva® (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV).

https://www.roche.com/media/store/releases/med-cor-2017-11-17.htm